A New Generation of Engineered Immune Cells
CAR-T cell therapy has transformed the treatment of several hematological malignancies, but its clinical deployment remains constrained by patient-specific manufacturing, treatment delays, allogeneic compatibility and potentially severe toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
These limitations have accelerated interest in CAR-engineered natural killer cells (CAR-NK cells). Unlike conventional autologous CAR-T approaches, CAR-NK technologies offer a potential route toward allogeneic, standardized and off-the-shelf cellular immunotherapies.
Their promise goes beyond replacing one immune cell with another. CAR-NK development combines innate tumor recognition, genetic engineering, multiple cellular sources and scalable production strategies, creating a distinctive platform for next-generation cancer immunotherapy.
Combining CAR Targeting with Natural NK Cell Cytotoxicity
NK cells are innate immune effectors capable of recognizing malignant or virus-infected cells without prior antigen sensitization. Their activity is controlled by a balance between activating and inhibitory signals.
CAR engineering adds tumor-specific recognition while preserving these natural cytotoxic mechanisms. CAR-NK cells can therefore combine CAR-dependent targeting with endogenous pathways involving NKG2D, natural cytotoxicity receptors and CD16-mediated antibody-dependent cellular cytotoxicity (ADCC).
This dual mechanism is particularly attractive because tumor control does not rely exclusively on a single engineered receptor.
Engineering CARs Around NK Biology
CAR-NK design is increasingly moving beyond architectures inherited from CAR-T cells. Modern constructs incorporate signaling components better adapted to NK-cell biology, including 2B4, DAP10, CD28H, OX40 and CD3ζ. Different combinations can influence cytotoxicity, activation and persistence.
At the same time, CRISPR/Cas9 and other gene-engineering technologies are expanding what can be programmed into CAR-NK cells. Researchers are targeting pathways involved in persistence, inhibitory signaling, tumor resistance, immune rejection and fratricide.
Multitarget CAR designs are also emerging to reduce antigen escape. Strategies targeting combinations such as CD19/CD22, CD19/CD20 or BCMA/GPRC5D illustrate the movement toward increasingly sophisticated tumor-recognition systems.
Improving Persistence and Resistance to the Tumor Microenvironment
One of the main limitations of CAR-NK therapy is the relatively short in vivo persistence of NK cells.
Strategies involving IL-15 signaling, membrane-bound cytokine systems, CISH knockout and memory-like NK phenotypes are being investigated to improve survival and expansion while limiting systemic toxicity.
Engineering is also being used to help CAR-NK cells withstand the tumor microenvironment. Inhibitory pathways such as TIGIT and NKG2A, suppressive TGF-β signaling and inadequate tumor trafficking are among the mechanisms being targeted to maintain cytotoxic activity under challenging conditions.
These developments are progressively transforming CAR-NK cells into highly programmable therapeutic platforms.
Multiple Cell Sources Enable the Off-the-Shelf Model
One of the most distinctive advantages of CAR-NK technology is the diversity of potential cellular sources.
CAR-NK cells can be generated from peripheral blood, umbilical cord blood, NK-92 cells, hematopoietic progenitors, hESCs and iPSCs.
Among these approaches, iPSC-derived NK cells are particularly relevant to industrial standardization. Their extensive expansion capacity and compatibility with genetic engineering create opportunities to establish renewable and defined cellular sources from which multiple therapeutic batches could be generated.
This changes the manufacturing paradigm. Instead of producing a unique cell product for each patient, CAR-NK platforms could support banked, standardized allogeneic products manufactured in advance and available when required.
Figure 1. Overview of CAR-NK cell sources, engineering strategies, expansion and downstream preparation for clinical administration.
The Role of the SoftXS in NK Cell Expansion
The transition toward standardized CAR-NK production creates a strong opportunity for advanced culture technologies capable of combining gentle cell handling, homogeneous culture conditions, reproducibility and scalability.
Cellura’s SoftXS™ platform uses a bladeless mixing principle designed to maintain homogeneous culture conditions while limiting hydrodynamic shear. This approach is particularly relevant during the cell expansion stage, where maintaining cellular quality while increasing production scale represents a key manufacturing challenge.
Cellura has already obtained strong experimental results using SoftXS™ for NK cell culture and expansion, demonstrating the potential of controlled low-shear hydrodynamic conditions to support these sensitive immune-cell workflows.
These results reinforce the relevance of SoftXS™ as a platform for the development and optimization of scalable NK and CAR-NK manufacturing processes, with the objective of supporting more controlled, reproducible and standardized cell production across scales.
Clinical Translation Is Accelerating
The CAR-NK clinical landscape is expanding rapidly. The review identified 73 clinical trials evaluating CAR-NK cells as the primary intervention using data current through November 3, 2025. Most remained in early development, with 74% in Phase I and 21% in Phase I/II.
CD19 remained the leading target, while BCMA, NKG2D, CD33, CD123 and emerging targets such as CD70, CD38 and GPRC5D illustrate the diversification of the field. Major indications include AML, B-cell non-Hodgkin lymphoma and multiple myeloma.
Despite this momentum, no CAR-NK therapy has yet received regulatory approval, emphasizing that the technology remains an emerging therapeutic field.
Toward Truly Off-the-Shelf Cancer Immunotherapy
CAR-NK therapy brings together innate cytotoxicity, CAR-mediated recognition, genome engineering, allogeneic cell sourcing and standardized production.
Its future will depend not only on designing more powerful cells, but also on overcoming persistence, immune rejection and antigen escape while establishing efficient expansion and preservation strategies.
Ultimately, the field is moving toward a different model of cellular immunotherapy: engineered immune cells produced from standardized sources, cryopreserved and potentially available for repeated administration without patient-specific manufacturing.
Achieving this vision will require progress in genetic engineering, therapeutic combinations and robust manufacturing platforms capable of delivering consistent and scalable cell supplies.
For CAR-NK therapy, the transition from engineered cell to standardized off-the-shelf product may be one of the defining challenges of the next generation of cancer immunotherapy.
Scientific background: CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies, Molecular Cancer, 2026.
